Timing of Immunotherapy for Advanced Kidney Cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether giving immunotherapy (nivolumab and ipilimumab) at a specific time of day can improve survival in people with advanced kidney cancer. It compares infusions before 11:30 a.m. versus after 1:30 p.m.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced clear cell kidney cancer (a specific type).
- Your doctor has said you can receive the standard immunotherapy combination of nivolumab and ipilimumab.
- You can schedule your infusion appointments either before 11:30 a.m. or after 1:30 p.m. for the first 4 cycles.
- You do not work night shifts, have a poorly controlled sleep disorder, or have recently traveled across 2+ time zones.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the time of day you receive immunotherapy (in the morning vs. later) affects how well it works. It is for people with advanced lung cancer or other solid tumors who are just starting or continuing PD-1/PD-L1 inhibitor treatment.
This trial studies the timing of a standard immunotherapy combination for advanced melanoma that cannot be removed by surgery or has spread. It aims to understand how timing affects treatment results.
This trial compares two immunotherapy combinations—nivolumab/relatlimab/ipilimumab vs. nivolumab/ipilimumab—as first treatment for advanced kidney cancer with clear cell features. It aims to see which combo works better for people who haven't had prior therapy.
This trial compares removing the kidney tumor right away versus waiting, while both groups receive the immunotherapy drugs ipilimumab and nivolumab. It is for people with advanced kidney cancer that has spread to other parts of the body.
This trial compares giving immunotherapy in the morning versus the afternoon to see if timing affects how well it works. It is for people with certain types of advanced or metastatic solid tumors who have not had this treatment before.
This trial tests a new oral drug (HC-7366) combined with two immunotherapy drugs (nivolumab and ipilimumab) for people with advanced clear cell kidney cancer. The goal is to see if adding this new drug can help shrink tumors or slow the cancer's growth.
Hear when a new Advanced Kidney Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.